Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2003-07-08
2009-12-15
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S686000, C514S748000, C514S764000, C514S766000
Reexamination Certificate
active
07632870
ABSTRACT:
The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).
REFERENCES:
patent: 3558612 (1971-01-01), Kuhn et al.
patent: 3994955 (1976-11-01), Sprenger
patent: 4190671 (1980-02-01), Vanstone et al.
patent: 4656305 (1987-04-01), Vanstone et al.
patent: 5276058 (1994-01-01), Satoh et al.
patent: 5326670 (1994-07-01), Kotachi et al.
patent: 5523302 (1996-06-01), Cain et al.
patent: 7385082 (2008-06-01), Delhomel et al.
patent: 2005/0176808 (2005-08-01), Najib et al.
patent: 43 27 365 (1995-02-01), None
patent: 0 947 511 (1999-10-01), None
patent: 1 254 658 (2002-11-01), None
patent: 1 254 759 (2002-11-01), None
patent: 2 248 829 (1975-05-01), None
patent: 2 383 157 (1977-08-01), None
patent: 78 06279 (1978-10-01), None
patent: 2 841 900 (2004-01-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 00/23073 (2000-04-01), None
patent: WO 01/98291 (2001-12-01), None
patent: WO 2004/005233 (2004-01-01), None
patent: WO 2004/005243 (2004-01-01), None
French KL, Angel AJ, Williams AR, Douglas RH, and Beam CF, “A New Preparation of Substituted 4H-1-Benzothiopyran-4-ones from C(a),N-Benzyolhydrazones or C(a),N-Carboalkoxyhydrazones and Methyl Thiosalicylate,” Journal of Heterocyclic Chemistry, 1998, 35, 45-48.
Byrn, et al., “Solid State Chemistry of Drugs,” 2nd ed., SSCI, Inc., Chapter 10, p. 232-247, 1999.
U.S. Appl. No. 10/520,079, filed Apr. 2005, Najib et al.
U.S. Appl. No. 11/493,040, filed Jul. 2006, Delhomel et al.
King, F.D. (Ed.), “Bioisosteres, conformational restriction and pro-drugs—case history: an example of a conformational restriction approach,” Medical Chemistry: Principles and Practice, 1994, Chapter 14, 206-209.
Shibata et al, “Anti-Tumorigenic Chalcones”, Stem Cells, Alphamded Press, Dayton, OH, US, vol. 12, 1994, pp. 44-52.
Dimmock et al, “Bioactivities of Chalcones”, Current Medicinal Chemistry, Bentham Science Publishers BV, BE, vol. 6, No. 12, 1999, pp. 1125-1149.
Lebeau et al, “Antioxidant Properties of Di-Tert-Butylhydroxylated Flavonoids”, Free Radical Biology and Medicine, Elsevier Science, XX, vol. 29, No. 9, Nov. 1, 2000, pp. 900-912.
Mukherjee et al, “Synthetic and Biological Activity Evaluation Studies on Nove, 1,3-diarylpropenones”, Bioorganic & Medicineal Chemistry, Elsevier Science LTD, GB, vol. 9, No. 2, 2001, pp. 337-345.
Rajakumar et al, “Antioxidant Properties of Phenyl Styryl Ketones”, Free Radical Research, Yverdon, CH, vol. 22, No. 4, 1995, pp. 309-317.
Arty, “Synthesis of benzylideneacetophenones and their inhibition of lipid peroxidation”, European Journal of Medicinal Chemistry 2000 France, vol. 35, No. 4, 2000, pp. 449-457.
Halliwell, “Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?”, ACTA Neurologica Scandinavica. Supplementum. Denmark 1989, vol. 126, 1989, pp. 23-33.
Sogawa et al, “3,4-Dihydroxychalcones as Potent 5-Lipoxygenase and Cyclooxygenase Inhibitors”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 36, No. 24, 1993, pp. 3904-3909.
Nakamura et al, “Synthesis and Biological Activities of Fluorinated Chalcone Derivativs”, Bioorganic & Medicinal Chemistry, Elsevier Science Ltd, GB, vol. 10, No. 3, Mar. 2002, pp. 699,706.
Calliste et al, “Chalcones: Structural Requirements for Antioxidant, Estrogenic and Antiproliferative Activities”, Anticancer Research, Helenic Anticancer Institute, Athens, GR, vol. 21, No. 6A, 2001, pp. 3949-3956.
Furmn et al, “Di-tert-Butylhydroxylated Flavonoids Protect Endothelial Cells Against Oxidized LDL-Induced Cytotocity”, Journal of Biochemical and Molecular Toxicology, Wiley, New York, NY, US, vol. 15, No. 5, 2001, pp. 270-278.
Lim et al, “Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues”, Journal of Pharmacy and Pharmacology, London, GB, vol. 53, No. 5, May 2001, pp. 653-668.
Patent Abstracts of Japan, vol. 018, No. 415, Aug. 4,1994 & JP 06 122623 A, May 6, 1994.
Patent Abstracts of Japan, vol. 012, No. 209, Jun. 15, 1988 & JP 63 010720 A, Jan. 18, 1988.
Haraguchi et al, “Antioxidative and Superoxide Scavenging Activities of Retrochalcones in Glycyrrhiza Inflata”, Bioorganic & Medicinal Chemistry, Elsevier Science Ltd, GB, vol. 6, No. 3, Mar. 1998, pp. 339-347.
Chemical Abstracts Service XP002236041, abstract & Oganesyan et al, “Study of structure-activity (A) interrelations in the flavonoid series. I. Synthesis of chalcome derivatives and quantitative SA analysis”, Khimiko-Farmatseviicheskii Zhurnal, vol. 20, No. 6, 1986, pp. 696-702.
Hsu et al, Structure-Activity Relationships of Substituted Flavonoids. (I), Taiwan-Kexue—Formosanscience, Taipei, TW, vol. 27, No.1/2, 1973, pp. 23-26.
Szajda et al, “New alkoxycarbonylalkyl oxychalcones and their alpha, beta-dibromo derivatives of potential antimicrobial activity”, Die Pharmazie, Germany, East Mar. 1989, vol. 44, No. 3, Mar. 1989. pp. 190-191.
Stoll et al, “Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53”, Biochemistry, American Chemical Society. Easton, PA, US, vol. 40, No. 2, Jan. 16, 2001, pp. 336-344.
Database, Chemical Abstracts Service, XP002271329, abstract & Shi et al, “Synthesis of ethyl flavone (or chalcone) oxyisobutyrate and its derivatives as antilipemic agents”, Taiwan Yaoxue Xazhi, vol. 27, No. 1-2, 1975, pp. 12-16.
Database Chemical Abstracts Service, XP002271330, abstract & Palanowski et al, “Synthesis of potentiao vasoactive compounds. I. phenylacrylophenone derivatives”, ACTA Poloniae Pharmaceutica (English Translation), vol. 24, No. 6, 1967, pp. 567-574.
Database, Chemical Abstracts Service, XP002271331, abstract & JP 54 019947 A (Taisho Pharmaceutical Co.) Feb. 15, 1979.
Database, Chemical Abstracts Service, XP002271332, abstract & Safak et al, “Chalcones. II. Synthesis of some chalcone derivatives and their antifungal activity against Candida albicans”, Fabad Farmasotik Bilimler Dergisi, vol. 8, No. 2, 1983, pp. 80-88.
Database, Chemical Abstracts Service, XP002271333, abstract & JP 05 255655 A, (Kanebo Ltd), Oct. 5, 1993.
Database, Chemical Abstracts Service, XP002271334, abstract & Sun et al, “Studies on flavonoids. VIIII. Synthesis of 7-substituted flavones and 2′,4-dihydroxy-3-methoxy-4′-substituted chalcones”, Gaodeng Xuexiao Huaxue Xuebao, vol. 9, No. 8, 1988, pp. 853.855.
Database, Chemical Abstracts Service, XP002271335, abstract &Szajda et al, Carbon 13 NMR study of o-, m- and p-′(alkoxycarbonyl)alkoxy chalcones and their alpha, beta dibromo derivatives, Magnetic Resonance in Chemistry, vol. 27, No. 4, 1989, pp. 399-402.
Cheng et al, “Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages”, Biochemical Pharmacology 61 (2001) 939-946.
Cheng et al, “Antioxidant properties of butein isolated from Dalbergia odorifera”, Biochemica et Biophyics Acta 1392 (1908) 291-299.
Hsieh et al, “Synthesis and Anti-inflammatory Effect of Chalcones and Related Compounds”,
Caumont-Bertrand Karine
Najib Jamila
Genfit
Hui San-ming
Nixon & Vanderhye P.C.
Zarek Paul
LandOfFree
Composition based on substituted 1,3-diphenylprop-2-en-1-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition based on substituted 1,3-diphenylprop-2-en-1-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition based on substituted 1,3-diphenylprop-2-en-1-one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105377